Cargando…

High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma

PURPOSE: To evaluate our institutional experience combining carboplatin-paclitaxel (C/T) chemotherapy with high-dose-rate (HDR) intra-vaginal brachytherapy (IVB) following comprehensive surgical staging in localized uterine serous carcinoma (USC). MATERIAL AND METHODS: Institutional chart review ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damast, Shari, Higgins, Susan A., Ratner, Elena, De Leon, Maria C., Mani, Sheida, Silasi, Dan-Arin, Azodi, Masoud, Santin, Alessandro, Rutherford, Thomas, Schwartz, Peter E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371058/ https://www.ncbi.nlm.nih.gov/pubmed/25829935 http://dx.doi.org/10.5114/jcb.2015.48539

Ejemplares similares

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

Stage III uterine serous carcinoma: modern trends in multimodality treatment
por: Li, Jessie Y., et al.
Publicado: (2020)

Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer
por: Qian, Jack M., et al.
Publicado: (2017)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
por: Cocco, E, et al.
Publicado: (2009)

Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review
por: Damast, Shari, et al.
Publicado: (2016)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

Vaginal Cuff Dehiscence in Robotic-Assisted Total Hysterectomy
por: Kashani, Shabnam, et al.
Publicado: (2012)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic
por: Damast, Shari, et al.
Publicado: (2022)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015)

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma
por: Cocco, E, et al.
Publicado: (2010)

GSOR10 Presentation Time: 3:15 PM: Single Implant Hybrid Interstitial Brachytherapy for Cervical Cancer during the COVID-19 Pandemic: An Institutional Approach
por: Damast, Shari, et al.
Publicado: (2021)

Robotic Versus Abdominal Hysterectomy for Very Large Uteri
por: Silasi, Dan-Arin, et al.
Publicado: (2013)

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGF(c )chimeric protein targeting tissue factor
por: Cocco, Emiliano, et al.
Publicado: (2011)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer
por: Silasi, Dan-Arin, et al.
Publicado: (2007)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

A Simple Approach to Specimen Retrieval via Posterior Colpotomy Incision
por: Clark, Lindsay E., et al.
Publicado: (2015)

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer
por: Albright, Benjamin B., et al.
Publicado: (2018)

Robotic-Assisted Laparoscopic Hysterectomy: Outcomes in Obese and Morbidly Obese Patients
por: Gallo, Taryn, et al.
Publicado: (2012)

Vaginal cuff dehiscence after vaginal cuff brachytherapy for uterine cancer. A case report
por: Cattaneo, Richard, et al.
Publicado: (2013)

Successful Treatment of Primary Vaginal Papillary Serous Adenocarcinoma Using Chemoradiation Followed by Brachytherapy
por: McCurdy, M., et al.
Publicado: (2009)

The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review
por: Lancellotta, Valentina, et al.
Publicado: (2020)

Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer
por: Seifi, Farinaz, et al.
Publicado: (2019)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Improved survival of patients with hypermutation in uterine serous carcinoma
por: Santin, Alessandro D., et al.
Publicado: (2015)

Brachytherapy for Central Serous Chorioretinopathy
por: Arora, Supriya, et al.
Publicado: (2022)

Transvaginal Morcellation
por: Clark Donat, Lindsay, et al.
Publicado: (2015)

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
por: Santin, A D, et al.
Publicado: (2005)

Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study
por: Webster, Emily M., et al.
Publicado: (2020)

Reliability of algebraic sum to evaluate adjuvant pelvic radiotherapy and vaginal cuff brachytherapy cumulative doses in uterine cancers
por: Casale, Michelina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ne24fgh1qfd0jbi0lqlv9rb6ue